Novo Nordisk A/S Class B Total Revenue

As of the most recent data (June 2026), NONOF shows a total revenue of $330B. That compares with $310B in the prior-year period — up 5.6% year over year. That is above the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NONOF's total revenue is now $330B (was $310B) — a 5.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. Novo Nordisk A/S Class B is at $330B, which is higher that average. That is roughly 201.9% above the sector mean. Use the comparison chart on this page to see how NONOF stacks up against individual peers as well.

Tracking NONOF's total revenue over time shows whether Novo Nordisk A/S Class B is scaling, shrinking, or reshaping that part of the business. The current reading is $330B That compares with $310B in the prior-year period — up 5.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $330B) with ownership activity and broader fundamentals.